Institute of Medical Biology
A*STAR

ExoCoBio
Exosomes for Your Health & Future

Seminar Announcement

-All are welcome-



Speaker: Dr. Yong Weon Yi, PhD
CTO |Managing Director
ExoCoBio Exosome Institute (EEI)
ExoCoBio Inc. South Korea

Title: **The effect of mesenchymal stem cell exosomes on atopic dermatitis in a mouse model**

Date: 8th December 2017 (Friday)

Host: Dr. Lim Sai Kiang

Time: 11.00 am to 12.00 pm

Venue: Creation theatrette, Lvl 4 Matrix, Biopolis

About the speaker:

Yong Weon Yi graduated with a Bachelor's degree in Molecular Biology at Seoul National University in 1994. He went on to pursue a Master's degree in Molecular Genetics in the same university and subsequently attained his PhD in Nanobiomedicine from Dan Kook University in 2015. His dynamic research experience has included gene therapy in Samyang Genex, developing a technology for detecting small molecule-protein kinase interactions in live cells in Mediscov Inc. and anti-cancer drug research in Georgetown University. Dr Yi was also a senior scientist and later a senior manager in Logos Biosystems from 2014 to 2016 which specializes in developing a series of automated systems and imaging instruments for laboratories engaging in research with a cellular and molecular emphasis.

Dr Yi is presently the Chief Technology Officer, Managing Director and R&D Division Director at the ExoCoBio Exosome Institute (EEI) in South Korea. The company was established in January 2017 by reputable exosome scientists and experienced management to develop innovative biopharmaceuticals and cosmeceuticals based on stem cell-derived exosomes. It is a venture-backed start-up that develops exosome-based cosmeceuticals and biopharmaceuticals for skin and tissue regeneration. The company has raised a total of US $11 million in its Series A funding round, within four months of its establishment, making ExoCoBio the largest and fastest investment attraction in South Korea. It has raised a total of approximately US $13.5 million and is establishing R&D and GMP facilities to commercialize exosome-based cosmeceuticals. In the long term, ExoCoBio plans to develop innovative exosome-based biopharmaceuticals for major diseases with unmet medical needs.

Exosomes are nano-vesicles between 30 and 150 nm, secreted by cells for intercellular signaling. They contain a variety of physiologically active substances and play key roles in important cellular processes. In particular, exosomes secreted by stem cells have been found to stimulate cellular regeneration and can be used for a wide range of tissue regeneration applications such as the growth of skin and hair. Exosomes have recently been a hot topic in biotechnology and many are investing heavily in the commercialization of exosomes.